Elin Julianti

Dr. Elin Julianti

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MAMuhammad Azhari
Muhammad Azhari
NMNovi Merliani
Novi Merliani
MSMarlia Singgih
Marlia Singgih
Masayoshi AraiMasayoshi Arai
Masayoshi Arai
EJElin Julianti
Elin Julianti
Tuberculosis (TB) poses a persistent global health threat exacerbated by the emergence of drug-resistant strains; hence, there is a continuous quest for novel antimicrobial agents. Despite efforts to develop effective therapies, existing treatments require a relatively long duration of therapy to eradicate the pathogen due to its virulence factors, pathogenesis patterns, and ability to enter dormant states. This can lead to a higher risk of treatment failure due to poor patient adherence to the complex regimen. As a result, considerable research is necessary to identify alternative antituberculosis agents. The marine environment, particularly marine-derived fungi, has recently gained interest due to its potential as an abundant source of bioactive natural products. This review covers 19 genera of marine-derived fungi and 139 metabolites, 131 of which exhibit antimycobacterial activity. The integrated dataset pinpoints the fungal genera and chemical classes that most frequently yield potent antimycobacterial hits while simultaneously exposing critical gaps, such as the minimal evaluation of compounds against dormant bacilli and the presence of underexplored ecological niches and fungal genera. Several compounds exhibit potent activity through uncommon mechanisms, including the inhibition of mycobacterial protein tyrosine phosphatases (MptpB/MptpA), protein kinase PknG, ATP synthase and the disruption of mycobacterial DNA via G-quadruplex stabilization. Structure–activity relationship (SAR) trends are highlighted for the most potent agents, illuminating how specific functional groups underpin target engagement and potency. This review also briefly proposes a dereplication strategy and approaches for toxicity mitigation in the exploration of marine-derived fungi’s natural products. Through this analysis, we offer insights into the potency and challenges of marine-derived fungi’s natural products as hit compounds or scaffolds for further antimycobacterial research.

1 January 2025 in Narra J
Verified
Journal Article
Open access
PDF file
PNPerdina Nursidika
Perdina Nursidika
EJElin Julianti
Elin Julianti
NKNeng Fisheri Kurniati
Neng Fisheri Kurniati
The increasing prevalence of azole resistance in various fungal species presents a significant concern, highlighting the urgent need for new antifungal agents. The aim of this study was to investigate the antifungal activity of fractions from Caulerpa racemosa, C. lentillifera, and caulerpin against three species: Aspergillus flavus, A. niger, and Candida albicans. The Caulerpa extracts were obtained through maceration with 96% ethanol, followed by fractionation using vacuum liquid chromatography. Antifungal activity was assessed using the broth microdilution method, while fungal growth kinetics were evaluated through time-kill curves. Bioautography was employed to identify inhibitory compounds, while liquid chromatography high-resolution mass spectrometry (LC-HRMS) was utilized to detect the contents of the extracts and fractions. Scanning electron microscopy (SEM) was used to observe the fungal structure, and the absorbance at 260/280 nm was measured to evaluate the cell leakage. LC-HRMS identified numerous compounds in C. racemosa and C. lentillifera with antifungal activities, including fatty acids, terpenes, alkaloids, flavonoids, and coumarins. The results indicate that the fractions of both Caulerpa did not inhibit the growth of A. flavus and A. niger, but effectively inhibited C. albicans. Among the fractions, F3CR and F4CL exhibited the highest antifungal efficacy against C. albicans, with minimum inhibitory concentrations (MICs) ranging from 64 to 128 µg/mL. Caulerpin, the primary metabolite of Caulerpa, also demonstrated significant inhibition, with an MIC of 256 µg/mL. The findings suggested that F3CR, F4CL, and caulerpin possessed fungistatic properties. Bioautography results revealed clear zones in the colonies, indicating inhibited fungal growth. The SEM observations showed that fungal cells became rough, perforated, and damaged, which was confirmed by the increase in absorbance at 260/280 nm, suggesting the release of cellular components such as nucleotides and proteins. In conclusion, both Caulerpa species and caulerpin are promising candidates for developing new antifungal agents against C. albicans.

1 January 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
MAMuhammad Azhari
Muhammad Azhari
ALAtik Pereztia Litanjuasari
Atik Pereztia Litanjuasari
MSMarlia Singgih
Marlia Singgih
Masayoshi AraiMasayoshi Arai
Masayoshi Arai
apt. Dian Handayaniapt. Dian Handayani
apt. Dian Handayani
EJElin Julianti
Elin Julianti
Context: Tuberculosis requires long therapy (6-9 months) to eradicate the tubercles from the body completely. This is partly caused by the ability of Mycobacterium tuberculosis to induce a dormant state that exhibits a resistant phenotype against recent antituberculosis. Hence, alternative compounds are required, especially the ones that are active against both active and dormant Mycobacterium. Marine-derived fungi are known to be a prolific source of bioactive secondary metabolites. Aims: To evaluate the isolated fungi from marine resources and investigate their antimycobacterial activity in aerobic and hypoxic conditions. Methods: The research included marine sources sampling, isolation of fungi, fermentation, and screening for antimycobacterial activity against Mycobacterium smegmatis in aerobic conditions. The chosen fungi isolates were continued with molecular identification and further investigation against hypoxic-induced dormant M. smegmatis. The antimycobacterial activity is determined using the microdilution method and visualization by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Results: As many as 49 fungi were successfully isolated from 40 marine samples, with two fungi exhibiting promising results, namely FSPL 3 (identified as Aspergillus ostianus) and FSB 34 (identified as Aspergillus flavus). The highest activity was shown by A. ostianus media ethyl acetate extracts, with the minimum inhibitory concentration (MIC) of 6.25 µg/mL against active and dormant M. smegmatis, followed by A. ostianus biomass and A. flavus media ethyl acetate extracts with the MIC of 25 µg/mL against both active and dormant M. smegmatis. Conclusions: The ethyl acetate extracts of A. ostianus media showed prospective activity to investigate further the active compounds as anti-dormant mycobacterial.

10 November 2023 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
EJElin Julianti
Elin Julianti
MAMuhammad Azhari
Muhammad Azhari
MSMarlia Singgih
Marlia Singgih
FAFitri Siti Dzurriyyah Aminah
Fitri Siti Dzurriyyah Aminah
MPMasteria Yunovilsa Putra
Masteria Yunovilsa Putra
MAMasayoshi Arai
Masayoshi Arai

1 May 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
PNPerdina Nursidika
Perdina Nursidika
EJElin Julianti
Elin Julianti
NKNeng Fisheri Kurniati
Neng Fisheri Kurniati
Context: Caulerpa racemosa is a green alga showing significant potential as a medicinal raw material without any currently available associated safety information. Aims: To assess the safety of C. racemosa ethanolic extract (CRE) through oral administration to mice and rats in acute and subchronic stages. Methods: In the acute toxicity test, mice were divided into the control group, and a group was administered 5000 mg/kg CRE. Mortality and signs of toxicity were observed over 14 day period. For the repeated dose oral toxicity test, rats were divided into control, satellite, and treatment groups, each consisting of five rats. The treatment groups received CRE at doses of 50, 350, and 1050 mg/kg b.w., respectively. The satellite group was observed for 35 days, while other groups were monitored for 28 days. Results: No mortality or signs of toxicity were observed in the animal subjects administered with acute and repeated-dose treatments. Additionally, the treatments did not result in statistically significant changes in body weight and relative organ sizes, compared to the control group. The hematological and biochemical analyses showed no substantial changes, with all parameters remaining within normal limits. However, significant discrepancies were noted in the male animal group for red blood cell and platelet count, as well as alanine transaminase and triglyceride levels, although these values remained within normal ranges. Morphological examination of organs did not reveal any significant alterations. Conclusions: Based on an LD50 value exceeding 5000 mg/kg body weight and all other results obtained, CRE was considered safe for consumption and could serve as a potential candidate for medicinal use derived from natural sources

8 March 2026 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
TSTri Suciati
Tri Suciati
RVRafiqah Nur Viviani
Rafiqah Nur Viviani
TFTengku Ruhul Fajria
Tengku Ruhul Fajria
NSNova Suliska
Nova Suliska
RARahma Tri Agustin
Rahma Tri Agustin
EJElin Julianti
Elin Julianti